• Firm commitments secured to raise $5m through new share issue
• Board and management to subscribe for $0.2m under the Placement
• Strengthened balance sheet supports preparation for HEALEY ALS Platform Trial

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, has secured firm commitments from new and existing institutional and professional investors to raise $5m (before costs) at an issue price of $0.12 per share. In addition, the Board and management team will subscribe for $0.2m under the Placement, $130,000 of which is subject to shareholder approval. The Placement follows a series of recent clinical, regulatory, and operational milestones that have strengthened Neurizon's strategic position. Funds will be used to support preparations for Neurizon's planned entry in the HEALEY ALS Platform Trial in Q4 CY2025, pending FDA clearance of its IND, along with manufacturing, regulatory filings, and pre-clinical initiatives designed to expand the potential of NUZ-001 across other neurodegenerative diseases. The Placement price of $0.12 represents a 14.3% discount to the last trading price and a 18.9% discount to the 5-trading day VWAP. Petra Capital Pty Limited acted as sole lead manager and sole bookrunner to the Placement.

Funds will be used to support preparations for Neurizon's planned entry in the HEALEY ALS Platform Trial in Q4 CY2025, pending FDA clearance of its IND, along with manufacturing, regulatory filings, and pre-clinical initiatives.